Grünenthal Overview
- Year Founded
-
1946
- Status
-
Private
- Employees
-
4,122
- Latest Deal Type
-
Debt Refin.
- Financing Rounds
-
20
- Investments
-
22
Grünenthal General Information
Description
Developer of a pharmaceutical company designed to improve pain management and related diseases. The company offers innovative treatments and advanced medical technologies, enabling patients worldwide to experience better health and enhanced quality of life.
Contact Information
Website
www.grunenthal.comCorporate Office
- Zieglerstraße 6
- 52078 Aachen
- Germany
Corporate Office
- Zieglerstraße 6
- 52078 Aachen
- Germany
Grünenthal Timeline
Grünenthal Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Grünenthal Comparisons
Industry
Financing
Details
Grünenthal Competitors (41)
One of Grünenthal’s 41 competitors is Johnson&Johnson Innovative Medicine, a Venture Capital-Backed company based in Raritan, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Johnson&Johnson Innovative Medicine | Venture Capital-Backed | Raritan, NJ | ||||
| Amarin Corporation | Corporation | Dublin, Ireland | ||||
| Acura Pharmaceuticals | Formerly VC-backed | Palatine, IL | ||||
| Chiesi Farmaceutici | Private Debt Financed | Parma, Italy | ||||
| Tris Pharma | Private Debt Financed | Monmouth Junction, NJ |
Grünenthal Patents
Grünenthal Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026202313-A1 | Aryloxyacetamides | Pending | 27-Mar-2025 | ||
| WO-2026176034-A1 | Topical capsaicin for treating sleep disturbance and/or neuropathic pain | Pending | 20-Feb-2025 | ||
| US-20250368625-A1 | Piperazines | Pending | 29-May-2024 | ||
| AU-2025276960-A1 | Piperazines which act as sstr4 modulators | Pending | 29-May-2024 | ||
| WO-2025247982-A1 | Piperazines which act as sstr4 modulators | Pending | 29-May-2024 | C07D403/12 |
Grünenthal Signals
Grünenthal Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Grünenthal Investments & Acquisitions (22)
Grünenthal’s most recent deal was a Buyout/LBO with Stivarga for . The deal was made on 21-Sep-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Stivarga | 21-Sep-2026 | Buyout/LBO | Pharmaceuticals | ||
| Grünenthal Meds | 02-Mar-2026 | Secondary Transaction - Private | Other Pharmaceuticals and Biotechnology | ||
| Eli Lilly (Rights to Cialis in Mexico, Brazil and Colombia) | 02-Jun-2025 | Buyout/LBO | Buildings and Property | ||
| Valinor Pharma | 22-Jul-2024 | Buyout/LBO | Pharmaceuticals | ||
| Grünenthal Meds | 02-Aug-2023 | Joint Venture | Other Pharmaceuticals and Biotechnology |
Grünenthal Exits (2)
Grünenthal’s most recent exit was on 01-Jan-1993 from Laboratorios Medicamentos Internacionales. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Laboratorios Medicamentos Internacionales | 01-Jan-1993 | Completed |
|
||
| Laboratorios Medicamentos Internacionales | 01-Jan-1979 | Corporate | Completed |
Grünenthal Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Grt Us Holding | Morristown, NJ | 2018 | |
| Laboratorios Andromaco | Santiago, Chile | 1942 | |
| Valinor Pharma | Chicago, IL |
Grünenthal FAQs
-
When was Grünenthal founded?
Grünenthal was founded in 1946.
-
Where is Grünenthal headquartered?
Grünenthal is headquartered in Aachen, Germany.
-
What is the size of Grünenthal?
Grünenthal has 4,122 total employees.
-
What industry is Grünenthal in?
Grünenthal’s primary industry is Pharmaceuticals.
-
Is Grünenthal a private or public company?
Grünenthal is a Private company.
-
What is Grünenthal’s current revenue?
The current revenue for Grünenthal is .
-
How much funding has Grünenthal raised over time?
Grünenthal has raised $8.2B.
-
Who are Grünenthal’s investors?
NovaQuest Capital Management has invested in Grünenthal.
-
Who are Grünenthal’s competitors?
Johnson&Johnson Innovative Medicine, Amarin Corporation, Acura Pharmaceuticals, Chiesi Farmaceutici, and Tris Pharma are some of the 41 competitors of Grünenthal.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process